2024 PARTNERS

ITM
Expertise Partner

See More:

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a
new generation of radiomolecular precision therapeutics and diagnostics for hard-to treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners
through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life

www.itm-radiopharma.com

PharmaLogic
Program Partner

See More:

PharmaLogic - Innovation Partner

PharmaLogic is a world-class contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other diseases. PharmaLogic has decades of expertise in drug development from discovery to commercialization through atop-tier network of radiopharmacies in North America. The Company seeks to take the lead in the advancement of radiopharmaceutical technology for the benefit of patients worldwide. For more information, visit:

www.radiopharmacy.com

PSI CRO
Hosting Partner

See More:

PSI is a unique global CRO with offices and an operational presence of full-time operational staff in more than 50 countries. PSI is headquartered in Switzerland and is fully owned by the management team that created the company in 1995.PSI is known for its commitment to delivery and service, focus on global pivotal phase II and III trials, as well as exceptionally high repeat business rates.Biotech and pharma clients that work with PSI on global trials tend to stay with them for decades, which explains the company’s stability and steady organic growth supported by exceptionally low staff turnover rates. PSI’s mission is to be the best CRO in the world as measured by their employees, clients, investigators, and vendors.

https://psi-cro.com

BIOEMTECH
Innovation Partner

See More:

BIOEMTECH - Innovation Partner

BIOEMTECH is a fast-growing CRO that provides high-quality, cost-effective solutions through the unique combination of preclinical services and molecular imaging instrumentation. BIOEMTECH undertakes full studies for evaluating new compounds in our authorised laboratories. Moreover, BIOEMTECH has developed and commercialised the “eyes”, desktop cameras, suitable for whole-body, real-time imaging of radionuclides and dyes in mice. Very recently, BIOEMTECH “eyes” made feasible in
vivo imaging of alpha emitters including Pb-212 and Ac-225 in oncological mouse models.

www.bioemtech.com

BIOSYNTH
Innovation Partner

See More:

BIOSYNTH - Innovation Partner

Critical Raw Materials and Services for Diagnostics, Vaccines and Pharmaceuticals - where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivalled research product portfolio and end-to-end manufacturing services, we are science led and customer focused to solve problems and deliver key reagents at scale and quality. Our expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner

www.biosynth.com

Chelatec
Innovation Partner

See More:

Chelatec - Innovation Partner

Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted HYPERLINK radiotherapeutics to pharma and biotech.

With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, "in vitro assay and in vivo investigations capabilities.

Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package: all quality and non-clinical safety data required for translation of a radiopharmaceutical

www.chelatec.com

ISOTOPIA
Innovation Partner

See More:

ISOTOPIA - Innovation Partner

Isotopia is a global pharmaceutical company that develops, produces, and distributes cutting-edge diagnostic and therapeutic radioactive isotopes and advanced PET and SPECT radiotracers.
We are a multidisciplinary team of experts unified in the mission to expand healthcare providers’ power to diagnose and treat cancer, with greater precision and safety.

www.isotopia-gloabal.com

Minerva Imaging
Innovation Partner

See More:

Minerva Imaging - Innovation Partner

Minerva Imaging is a CRO and CDMO specialized in targeted radionuclide therapies and molecular imaging. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services.

Navigo Proteins
Innovation Partner

See More:

Navigo Proteins - Innovation Partner

Navigo Proteins is developing novel targeted radiopharmaceuticals based on its proprietary target binders called Affilin® ligands. Navigo’s Precision Targeting Toolbox enables custom-designing Affilin® Radiotheranostics by combining, mono-, bi- or multi-specific target binders with chelators, imaging/therapy radionuclides and proprietary half-life extending domains, creating the ideal candidate with fine tuneable affinity and pharmacokinetic profile. With a growing portfolio of Affilin® ligands against solid tumors and I/O targets, Navigo is looking for strategic partnerships to advance Affilin®-Radiotheranostics into clinical development.

www.navigo-proteins.com

RPO Group
Innovation Partner

See More:

RPO Group - Exhibition Partner

RPO Group is a Belgium based clinical CRO with a focus on early phase radiopharmaceutical drug development in precision oncology. Having a robust background in radiotheranostics & contract research, two (small batch) radiomanufacturing industrial partners, and a preferred (radiotheranostic) site network, RPO Group offers an integrated one-stop-shop approach to clients aiming to test the clinical potential of their radiotheranostic agents. RPO Group builds a body of evidence around these early compounds, delivers value from limited datasets, expedites drug development routes, and avoids tunnel vision in decision making.

www.rpo-scientific.com

SHINE
Innovation Partner

See More:

SHINE - Exhibition Partner

SHINE is a next-generation nuclear technology company, focused on deploying state-of-the-art fusion technology to help solve global problems and create a scalable path toward practical fusion energy. SHINE deploys its safe, cost-effective and environmentally-friendly technology in a step-wise approach, beginning with our systems used for advanced industrial imaging in non-destructive testing of components used in aerospace, defense, transportation, energy and other sectors. SHINE’s proprietary medical isotope production creates Molybdenum 99 and non-carrier-added Lutetium 177 used in tens of thousands of daily procedures to diagnose and treat heart disease and late-stage cancer. For more information, follow SHINE on Facebook, LinkedIn and Twitter.

www.shinefusion.com

TRASIS
Innovation Partner

See More:

Trasis - Innovation Partner

Trasis was founded in 2004 by Gauthier Philippart and Jean-Luc Morelle, the designers of the first radiosynthesisers to combine high-yield synthesis and GMP.

They put together their expertise and their knowledge of the radiopharmaceutical industry and founded Trasis, an innovative and forward-looking company. Trasis has now a track-record in developing instruments and methods recognized throughout the world.

At Trasis we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster. To this end, we design, manufacture, sell and support high performance synthesisers, dose preparation equipment, their shielding and accessories. We also develop customised synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs.

Our proven radiopharmaceutical expertise, coupled with our high end instruments allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorisation.

Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities and pharmaceutical companies

www.trasis.com

IONETIX
Exhibition Partner

See More:

IONETIX - Exhibition Partner

IONETIX is a full-service, end-to-end radiopharmaceutical solutions provider. Utilizing a proprietary cyclotron technology platform, Ionetix develops innovative accelerator solutions to produce medical radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. Ionetix is currently in the process of establishing the first commercial alpha isotope manufacturing and distribution facility dedicated to the production of Actinium-225 (Ac- 225) and Astatine-211 (At- 211). Ionetix will provide isotope production, drug manufacturing and distribution logistics for these alpha isotopes beginning in early 2023

www.ionetix.com

Scitech
Exhibition Partner

See More:

Scitech - Exhibition Partner

We provide pharmaceutical design and qualification consultancy, as well as qualification and validation for high value manufacturing, research, emerging technologies and highly regulated industries; this includes pharmaceutical, biotechnology, life sciences and radiopharmaceutical industries. We have a multidisciplinary team, with extensive experience across pharmaceutical design and qualification consultancy, cell gene therapy and animal health, to name a few.

www.scitech.com

OmniAb
Exhibition Partner

See More:

OmniAb - Exhibition Partner

OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industries and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence ™ (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics and many others.

www.omniab.com

Von Gahlen
Exhibition Partner

See More:

Von Gahlen - Exhibition Partner

Von Gahlen, founded in 1973, is a global leader in designing and manufacturing lead shielding products for radiopharmacy and nuclear medicine. From fully integrated hot cell
production lines with automated dispensing systems to Type A packaging solutions for transport, they deliver high-quality products that ensure safety and reliability. Focused on
protecting people, environments, and radiopharmaceuticals, Von Gahlen offers technological innovations and intelligent, ergonomic solutions for every production stage, meeting
industry standards while fostering lasting customer partnerships.

www.vongahlen.com

AtomVie
Event Partner

See More:

Leveraging over seven years of expertise in the GMP manufacturing and global distribution of radiotherapeutics, the Centre for Probe Development and Commercialization
(CPDC) is launching AtomVie Global Radiopharma Inc. (AtomVie), a global leading Contract Development and Manufacturing Organization (CDMO). AtomVie offers the full
range of scientific, technical, regulatory, quality, logistics, and Lu-177 supply combined with a specialized infrastructure for the development of your radiotherapeutics from
clinical Phase 1 to the commercial marketplace.

www.atomvie.com

NorthStar
Event Partner

See More:

NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company focused on advancing patient care by providing therapeutic and diagnostic radioisotopes, novel radiopharmaceuticals and customized radiopharmaceutical development services. Its proven management team and environmentally preferable, non-uranium based technologies have made it an emerging leader at the forefront of U.S. medical radioisotope and radiopharmaceutical production. NorthStar is poised to be the first commercialscale producer of non-carrier added (n.c.a.) actinium-225 (Ac-225) and copper-67 (Cu-67). Its Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) services unit will provide customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their programs.

www.northstarnm.com

Perceptive
Event Partner

See More:

At Perceptive, we empower pharmaceutical, biotech, and clinical research organizations to rapidly discover and advance life-changing medicines by delivering unmatched scientific
and technological expertise, global operational experience, and end-to-end solutions that ensure confident R&D decision-making. But we are not in the business of clinical
research. We are in the business of time and reassurance. In our world, time is more valuable than money. Time is lives. Where dependability and reliability are fundamental, we
deliver reassurance at the speed of life

www.perceptive.com

Time:Matters
Event Partner

See More:

Established in 2002, time:matters has emerged as a leader in customized and flexible logistics solutions. At time:matters, we specialize in high-performance logistics, providing time-critical solutions worldwide. From urgently needed spare parts to medical samples, dangerous goods, and important documents, we offer dedicated, reliable, and efficient transportation options
via air, rail, and road. Our comprehensive expertise seamlessly integrates and combines multiple modes of transport, ensuring flexibility and timely delivery. Whether it is a critical component
for the automotive industry or life-saving stem cells, we deliver solutions you can trust, because we understand the requirements of your shipments and are dedicated to meeting them.

3rd - 5th December, 2024
Amsterdam, NL

2024 PARTNERS

OUR CONTACT DETAILS

JOIN OUR TEAM

ABOUT US

EXPLORE OUR PRODUCTS

SEARCH

3rd - 5th December, 2024 Amsterdam, NL

2024 PARTNERS

OUR CONTACT DETAILS

JOIN OUR TEAM

ABOUT US

EXPLORE OUR PRODUCTS

SEARCH

3rd - 5th December, 2024
Amsterdam, NL